Patent · US Active

Dosing regimen for sedation with CNS 7056 (Remimazolam)

US12201637B2 · kind B2 · utility

0Cited by

40References

17Claims

0Family size

Assignee

PAION UK LIMITED · GB

Inventors

Karin Wilhelm-Ogunbiyi · Simmerath, DE
Keith Borkett · Romsey, GB
Gary Stuart Tilbrook · Huntingdon, GB
Hugh Wiltshire · Digswell, GB

Key dates

Filing date	Jul 10, 2023
Grant date	Jan 21, 2025
Priority date	—
Expiry date	Jul 25, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/20
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.